利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.027 秒)

    Antibodies against vascular endothelial growth factor receptor-1
    1.
    发明授权
    Antibodies against vascular endothelial growth factor receptor-1 有权
    抗血管内皮生长因子受体-1的抗体

    公开(公告)号：US08143025B2

    公开(公告)日：2012-03-27

    申请号：US13112152

    申请日：2011-05-20

    申请人： Yan Wu ,  Peter Bohlen ,  Daniel J. Hicklin

    发明人： Yan Wu ,  Peter Bohlen ,  Daniel J. Hicklin

    IPC分类号： C12P21/06 ,  C12P19/30 ,  C07H21/04

    CPC分类号： C07K16/2863 ,  A61K39/39541 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti-VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.

    摘要翻译： 对血管内皮生长因子受体1（VEGFR-1）特异的单克隆抗体。 本发明还提供编码核苷酸序列和包含可变重链和轻链免疫球蛋白分子的氨基酸序列，其包括对应于CDR1，CDR2和CDR3的互补决定区的序列。 本发明还提供了用于产生和表达抗VEGFR-1抗体的方法以及通过施用抗VEGFR-1抗体治疗血管生成相关病症并降低肿瘤生长的方法。

    ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY
    3.
    发明申请
    ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY 审中-公开
    VE-CADHERIN的抗体拮抗剂，对血管渗透性没有不良影响

    公开(公告)号：US20080311121A1

    公开(公告)日：2008-12-18

    申请号：US12056116

    申请日：2008-03-26

    申请人： Fang Liao ,  Daniel J. Hicklin ,  Peter Bohlen

    发明人： Fang Liao ,  Daniel J. Hicklin ,  Peter Bohlen

    IPC分类号： A61K39/395 ,  A61P9/00

    CPC分类号： C07K16/2896 ,  A61K48/00 ,  A61K2039/505 ,  C07K2317/34

    摘要： The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin. (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

    摘要翻译： 由抗体E4B9识别的鼠表位序列与人VE-钙粘蛋白共享100％同源性，因此检查该抗体以确定其是否与人VE-钙粘蛋白交叉反应。 表达人和鼠细胞的几种VE-钙粘蛋白的Western印迹分析表明E4B9确实与人VE-钙粘蛋白交叉反应。 （图6 ）。 该发现有助于开发“人源化”E4B9抗体及其在临床前发展中的成功，因为其抗肿瘤活性可以在几种小鼠模型中广泛测试。

    ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY
    4.
    发明申请
    ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY 审中-公开
    VE-CADHERIN的抗体拮抗剂，对血管渗透性没有不良影响

    公开(公告)号：US20080317750A1

    公开(公告)日：2008-12-25

    申请号：US12056146

    申请日：2008-03-26

    申请人： Fang LIAO ,  Daniel J. Hicklin ,  Peter Bohlen

    发明人： Fang LIAO ,  Daniel J. Hicklin ,  Peter Bohlen

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2896 ,  A61K48/00 ,  A61K2039/505 ,  C07K2317/34

    摘要： The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

    摘要翻译： 由抗体E4B9识别的鼠表位序列与人VE-钙粘蛋白共享100％同源性，因此检查该抗体以确定其是否与人VE-钙粘蛋白交叉反应。 表达人和鼠细胞的几种VE-钙粘蛋白的Western印迹分析表明E4B9确实与人VE-钙粘蛋白交叉反应（图6）。 该发现有助于开发“人源化”E4B9抗体及其在临床前发展中的成功，因为其抗肿瘤活性可以在几种小鼠模型中广泛测试。

    Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
    5.
    发明授权
    Antibody antagonists of VE-cadherin without adverse effects on vascular permeability 失效
    VE-钙粘蛋白的抗体拮抗剂对血管通透性无不良影响

    公开(公告)号：US07371574B2

    公开(公告)日：2008-05-13

    申请号：US10040128

    申请日：2002-01-02

    申请人： Fang Liao ,  Daniel J. Hicklin ,  Peter Bohlen

    发明人： Fang Liao ,  Daniel J. Hicklin ,  Peter Bohlen

    IPC分类号： C12N5/20

    CPC分类号： C07K16/2896 ,  A61K48/00 ,  A61K2039/505 ,  C07K2317/34

    摘要： The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VIE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine ceH indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the prectinical development since its anti-tumor activity can be tested extensively in several mouse models.

    摘要翻译： 由抗体E4B9识别的鼠表位序列与人VE-钙粘蛋白共享100％同源性，因此检查该抗体以确定其是否与人类VIE-钙粘蛋白交叉反应。 表达人和鼠CeH的几种VE-钙粘蛋白的Western印迹分析表明E4B9确实与人VE-钙粘蛋白交叉反应（图6）。 这一发现促进了“人源化”E4B9抗体的发展及其在临床前发展中的成功，因为其抗肿瘤活性可以在几种小鼠模型中进行广泛测试。

    ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY
    6.
    发明申请
    ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY 审中-公开
    VE-CADHERIN的抗体拮抗剂，对血管渗透性没有不良影响

    公开(公告)号：US20090060909A1

    公开(公告)日：2009-03-05

    申请号：US12056173

    申请日：2008-03-26

    申请人： Fang LIAO ,  Daniel J. Hicklin ,  Peter Bohlen

    发明人： Fang LIAO ,  Daniel J. Hicklin ,  Peter Bohlen

    IPC分类号： A61K39/395 ,  A61P9/00 ,  A61P19/02 ,  A61P37/00 ,  A61P27/02

    CPC分类号： C07K16/2896 ,  A61K48/00 ,  A61K2039/505 ,  C07K2317/34

    摘要： The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a “humanized” E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.

    摘要翻译： 由抗体E4B9识别的鼠表位序列与人VE-钙粘蛋白共享100％同源性，因此检查该抗体以确定其是否与人VE-钙粘蛋白交叉反应。 表达人和鼠细胞的几种VE-钙粘蛋白的Western印迹分析表明E4B9确实与人VE-钙粘蛋白交叉反应（图6）。 该发现有助于开发“人源化”E4B9抗体及其在临床前发展中的成功，因为其抗肿瘤活性可以在几种小鼠模型中广泛测试。